Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Abdulla A. Damluji, MD, PhD Profile picture
@DrDamluji
Nov 5, 2021 • 26 tweets • 17 min read • Read on X
Scrolly
SURTAVI

No differences in death ,stroke, MI, or HF between TAVR and Surgery during longer follow-up

#TCT2021
Hemodynamics

Total AR and PVL

KCCQ no difference after 1 year

NYHA class at one year 1
Summary for SURTAVI

Self expanding valve

#TCT2021
Excellent!
5 year data for 4,000 patients is now out (intermediate risk).

@djc795
Economic outcomes of PARTNER #3

@djc795

Cost effectiveness study along side of PARTNER 3 trial

funded by Edwards
Costing: definitions

US population only

Medicare data link
Results Baseline

TAVR vs SAVR PARTNER 3 Economic Study
Index Hospital Costs

Follow-up Cost
Overall no cost difference

QALY difference (borderline?!)

#TCT2021
All costs and effects discounting

TAVR is cost effective
Subgroups (pre-specified)

Sensitivity analyses

#TCT2021
Sensitivity Analyses
Summary!

84% CI that we will improve outcomes and at the same time achieve cost effectiveness.

10 year outcomes will affect cost effectiveness - to come...

Outstanding presentation @djc795 @DrMauricioCohen

#TCT2021
"When mortality rate is the same between SAVR and TAVR: patient preference is what matter next."

"No one wants a sternotomy."

@djc795

#TCT2021
CHOICE CLOSURE

Vascular Closure for TAVR but this also applies to shock space also (Safety Bundle)

#TCT2021

@Radial_ICG @behnam_tehrani @agtruesdell @ShashankSinhaMD @JACCJournals
Available Evidence

Aim Choice Closure

Randomization: pure plug based vs primary suture based

#TCT2021
Inclusion and Exclusion

Primary Endpoint
Secondary Endpoints

Study Methods

Angioseal was used...

3 Locations in Germany

#TCT2021
Study Flow

258 MANTA vs 258 ProGlide

#TCT2021
Baseline Results

Vessel Characteristics

Procedural Details

Low ultrasound use?! @Radial_ICG

#TCT2021
Manta had higher complications!!

Important data!

#TCT2021
Subgroup analysis

Hospital Outcomes

30-Day Outcomes

#TCT2021
Limitation
Conclusion

Excellent trial @Mo_A_W

Applies to shock too

***Editorializing: Losing the wire access with MANTA is a big problem.

#SafetyBundle

#TCT2021
Comparison of a Pure Plug-Based versus a Primary Suture-Based Vascular Closure Device Strategy for Transfemoral Transcatheter Aortic Valve Replacement: The CHOICE-CLOSURE Randomized Clinical Trial

@CircAHA

ahajournals.org/doi/abs/10.116…

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Abdulla A. Damluji, MD, PhD

Abdulla A. Damluji, MD, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DrDamluji

Abdulla A. Damluji, MD, PhD Profile picture
Mar 31
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism: @NEJM

🥸 - good work #ACC25 @ACCinTouch

👇👇👇 Image
🥸1️⃣ In cancer-associated VTE, extended anticoagulation is common—but the dose remains uncertain. The API-CAT trial tested reduced-dose vs. full-dose apixaban after 6 months of initial therapy.
🥸2️⃣ 1,766 patients with active cancer and prior VTE were randomized to apixaban 2.5 mg BID or 5 mg BID for 12 months. Median follow-up was nearly 12 months.
Read 21 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Mar 31
Global Effect of Cardiovascular Risk Factors on Lifetime Estimates: @NEJM

🥸 Great work from Germany on global life time risk of CVD risk

😱 Summary

👇👇👇 Image
🥸1️⃣ Lifetime cardiovascular risk increases with the number of classic risk factors you carry at age 50. The Global Cardiovascular Risk Consortium analyzed over 2 million people to estimate how much risk factors shorten life and healthspan.
🥸2️⃣ Five risk factors were studied: high blood pressure, high cholesterol, diabetes, smoking, and unhealthy body weight.
Read 22 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Mar 31
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a): @NEJM #ACC25

🥸This is a great trial

😱 Let's summarize

👇👇👇 Image
🥸1️⃣ Elevated concentrations of lipoprotein(a) are a strong, independent risk factor for cardiovascular disease. Lepodisiran, a long-acting small interfering RNA, targets hepatic production of lipoprotein(a).
🥸2️⃣ In the ALPACA trial, 320 adults with baseline lipoprotein(a) ≥175 nmol/L were randomly assigned to receive lepodisiran (16 mg, 96 mg, or 400 mg) or placebo.
Read 21 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Mar 1
2025 ACC/AHA/ACEP/NAEMSP/SCAI
Guideline for the Management of Patients
With Acute Coronary Syndromes: @CircAHA @JACCJournals

🥸Here are class 1 recommendations from the document; Massive effort - congratulations to the authors: @SVRaoMD

😱 Below

👇👇👇 Image
🥸1️⃣ In patients with suspected ACS, a 12-lead ECG should be acquired and interpreted within 10 minutes of first medical contact to identify patients with STEMI.
🥸2️⃣ In patients with suspected ACS in which the initial ECG is nondiagnostic of STEMI, serial ECGs to detect potential ischemic changes should be performed, especially when clinical suspicion of ACS is high, symptoms are persistent, or the clinical condition deteriorates.
Read 37 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Feb 3
The Physiology of Hunger: @NEJM

🥸 So this is not in CV medicine, but:
(1) it is interesting and (2) it has implications for CV

😱 Good job @NEJM - Summary

👇👇👇 Image
🥸 1️⃣ Hunger is an ancient survival mechanism that evolved to keep humans alive in times of food scarcity.
🥸 2️⃣ Early humans were hunter-gatherers, who faced unpredictable food supplies. Their bodies adapted to store energy efficiently, to help with survival during famine.
Read 21 tweets
Abdulla A. Damluji, MD, PhD Profile picture
Jan 28
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation: @NEJM

🥸Summary

👇👇👇 Image
🥸 1️⃣ Abelacimab significantly reduced bleeding in atrial fibrillation patients compared to rivaroxaban, as reported in the AZALEA–TIMI 71 trial.
🥸 2️⃣ Monthly subcutaneous abelacimab achieved a 99% reduction in free factor XI levels at 150 mg and 97% at 90 mg.
Read 21 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

Send Email!

:(